Medivation Inc (MDVN), Amarin Corporation plc (ADR) (AMRN), Abbott Laboratories (ABT): Adage Capital Management Owns 5.4% of This Company

According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation Inc (NASDAQ:MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has roughly doubled the size of its position. Find more of Adage’s stock picks. Biotechnology stocks have generally been strong this year, though Medivation Inc (NASDAQ:MDVN) is actually an exception having fallen year to date. Currently, Medivation Inc (NASDAQ:MDVN) primarily markets Xtandi, a cancer drug, to post-chemotherapy prostate cancer patients; the company is also studying the use of the drug in other contexts.

Xtandi launched last year and as a general rule the drug has been found to be more effective than competing drugs with some question as to the prevalence of side effects in some groups of patients (which may lead to it being a second-choice drug). Still, revenue numbers have been good and there is at least a prospect of the drug finding wider use if it is approved in other markets (including pre-chemotherapy prostate cancer). As a development stage company Medivation is unprofitable, and cash flow from operations was negative in 2012 as well at a net of about $100 million in cash used. At the end of the year there was about $300 million in cash, cash equivalents, and short term investments on the balance sheet so at least in the short term there should be few cash concerns.

Andreas Halvorsen

Analyst consensus is for earnings per share of 41 cents in 2014, with a wide range of estimates (from $1.93 per share to a loss of 50 cents per share). Billionaire and Tiger Cub Andreas Halvorsen’s Viking Global had been selling shares of Medivation Inc (NASDAQ:MDVN) between October and December of last year, but still closed 2012 with 3.4 million shares in its portfolio (see Halvorsen’s favorite stocks). Orbimed Advisors, a healthcare-focused fund managed by Sam Isaly, reported owning 1.4 million shares at the end of the fourth quarter (check out more stocks Isaly likes).

Other development stage biotechnology companies include Dendreon (NASDAQ:DNDN) and Amarin Corporation plc (ADR) (NASDAQ:AMRN). Consensus is that both of these companies will be unprofitable this year as well as in 2014, so any investment in them is at least as speculative as buying Medivation Inc (NASDAQ:MDVN). Dendreon’s lead product Provenge is also a prostate cancer drug, with the company working on other cancer treatments as well. The stock price has fallen 55% in the last year, and the most recent data shows that 34% of the float is held short so there continues to be a sizable bearish community. Amarin Corporation plc (ADR) (NASDAQ:AMRN) is also down considerably from its levels a year ago, and is also a popular short target; Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s lead product is designed to reduce triglyceride levels.

We can also compare Medivation Inc (NASDAQ:MDVN) to larger biotech companies including Abbott Laboratories (NYSE:ABT) and Biogen (NASDAQ:BIIB). These companies both generated positive earnings in 2012, though in Biogen’s case the trailing P/E is quite high at 34. While its recent financial performance has not been particularly encouraging- in the fourth quarter of 2012, revenue increased only 7% versus a year earlier and earnings were actually down slightly- the sell-side is expecting improvements in net income over the next couple years and so the forward P/E is only 20. We still think that we would avoid the stock for now. Abbott Laboratories (NYSE:ABT), meanwhile, carries a forward P/E of 16. It’s also not been in a particularly good situation, with earnings falling 35% in its most recent quarterly report compared to the fourth quarter of 2011.

We do expect earnings of these biotech companies to be a bit noisy but at this point it looks to us that Abbott Laboratories (NYSE:ABT) is too speculative to treat as a value stock as well as Biogen. The other three companies we’ve covered here, including Medivation, are yet to be profitable as well and so we’d advise against buying them as well. We do think that Medivation looks to be an unwise short given the emerging success of its drug and the sizable cash on the company’s balance sheet as it attempts to bring Xtandi into additional markets.

Disclosure: I own no shares of any stocks mentioned in this article.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!